Hoth Therapeutics, a clinical-stage biopharmaceutical company focused on therapies for underserved medical needs, has filed two US provisional patent applications that significantly expand its intellectual property portfolio and establish a new oncology-focused dermatology platform. The platform targets skin toxicities caused by modern cancer treatments, an area of growing unmet need as patients remain on therapy for longer durations.
The first provisional patent application covers the topical treatment of radiation-induced skin toxicity in oncology patients. The second addresses dermatologic toxicities linked to emerging targeted cancer therapies, including second- and third-generation menin inhibitors.
Together, the filings secure priority intellectual property rights around the use of HT-001 for treating dermatologic toxicities across multiple oncology treatment modalities, including radiation therapy and next-generation targeted agents. As advances in cancer treatment improve survival, the management of treatment-limiting skin toxicities has become increasingly critical in routine oncology care.
Radiation-induced dermatitis and skin adverse effects associated with targeted cancer therapies are common and can lead to pain, inflammation, severe itching, infection risk, diminished quality of life, and interruptions or discontinuation of cancer treatment, potentially affecting clinical outcomes. Despite their frequency, existing management options are largely supportive, with limited therapies designed to address the underlying biological mechanisms.
Hoth’s patent strategy seeks to protect the use of HT-001, a receptor antagonist with an established pharmacologic profile, to modulate neurogenic and inflammatory pathways involved in therapy-induced skin injury. The company views this approach as a potentially novel and first-in-class strategy within the expanding fields of oncology supportive care and oncodermatology.
The provisional filings are intended to support development of a scalable oncology-adjacent platform with potential applications across radiation oncology, targeted cancer therapies, dermatology, and inflammatory skin disorders. They also allow flexibility for further preclinical development, formulation optimisation, and future US and international patent filings.
Hoth Therapeutics continues to build a diversified, IP-driven development portfolio targeting large, underserved markets, with a focus on therapies designed to improve patient outcomes and quality of life.
